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Neuroprotection by the NSAID
Mefenamic Acid in an Experimental
Model of Stroke
Parto S. Khansari1* and Robert F. Halliwell2
1 School of Pharmacy and Pharmaceutical Sciences, Stony Brook University, Stony Brook, NY, United States, 2 Thomas J.
Long School of Pharmacy and Health Sciences, University of the Pacific, Stockton, CA, United States
Stroke is a devastating neurological event with limited treatment opportunities. Recent
advances in understanding the underlying pathogenesis of cerebral ischemia support
the involvement of multiple biochemical pathways in the development of the ischemic
damage. Fenamates are classical non-steroidal anti-inflammatory drugs but they
are also highly subunit-selective modulators of GABAA receptors, activators of IKS
potassium channels and antagonists of non-selective cation channels and the NLRP3
inflammosome. In the present study we investigated the effect of mefenamic acid
(MFA) in a rodent model of ischemic stroke and then addressed the underlying
pharmacological mechanisms in vitro for its actions in vivo. The efficacy of MFA in
reducing ischemic damage was evaluated in adult male Wistar rats subjected to a 2-
h middle cerebral artery occlusion. Intracerebroventricular (ICV) infusion of MFA (0.5
or 1 mg/kg) for 24 h, significantly reduced the infarct volume and the total ischemic
brain damage. In vitro, the fenamates, MFA, meclofenamic acid, niflumic acid, and
flufenamic acid each reduced glutamate-evoked excitotoxicity in cultured embryonic rat
hippocampal neurons supporting the idea that this is a drug class action. In contrast the
non-fenamate NSAIDs, ibuprofen and indomethacin did not reduce excitotoxicity in vitro
indicating that neuroprotection by MFA was not dependent upon anti-inflammatory
actions. Co-application of MFA (100 µM) with either of the GABAA antagonists picrotoxin
(100 µM) or bicuculline (10 µM) or the potassium channel blocker tetraethylammonium
(30 mM) did not prevent neuroprotection with MFA, suggesting that the actions of MFA
also do not depend on GABAA receptor modulation or potassium channel activation.
These new findings indicate that fenamates may be valuable in the adjunctive treatment
of ischemic stroke.
Keywords: ischemic stroke, MCAO, excitotoxicity, neuroprotection, fenamates
INTRODUCTION
Ischemic stroke is a major cause of human neurological morbidity and mortality and is associated
with a poor prognosis around the world (Maiese, 1998; Beresford et al., 2003). According to an
update by the American Heart Association, stroke remains the fourth leading cause of death in
United States with close to 800,000 new and recurrent cases annually (Benjamin et al., 2018).
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Significantly, a lack of efficacy in clinical trials of the drugs
directed at a single pharmacological or biochemical target has
raised the hypothesis that treatment of ischemic stroke may
require pharmacological interventions that can modulate a
number of activated pathways (Sweeney et al., 1995; Hammerman
and Kaplan, 1998; Lo et al., 2003).
Fenamates are classical non-steroidal anti-inflammatory
drugs that inhibit cyclooxygenases (Asanuma et al., 2001)
but additionally and possibly uniquely, they have a number
of significant other pharmacological actions relevant to the
pathogenesis of ischemic stroke. For example, several clinically
approved and widely used fenamates are effective and selective
inhibitors of the NLRP3 inflammasome via inhibition of the
volume-regulated anion channel in macrophages (Daniels et al.,
2016; Mangan et al., 2018). The fenamate meclofenamic acid
acts as an opener of Kv7.2/3 (KCNQ2/3) potassium channels
expressed in CHO cells; it enhances the M-current and
hyperpolarizes membrane potential and reduces action potentials
in cultured neurons (Peretz et al., 2005, 2007). The fenamate,
mefenamic acid (MFA) (Ponstel) is a highly subunit-specific
modulator of GABA currents, potentiating α1β2γ2 GABA
receptors but inhibiting α1β1γ2 GABA receptors expressed
in HEK293 cells or Xenopus oocytes (Halliwell et al., 1999).
Moreover, MFA potentiates and directly activates GABA-A
chloride currents in cultured rodent hippocampal neurons
(Coyne et al., 2007). In addition, niflumic and flufenamic acid,
inhibit NMDA-activated currents recorded from spinal neurons
(Lerma and Martin del Rio, 1992) and flufenamic acid has
been shown to block calcium activated non-selective cation
(CAN) channels in rat hippocampal CA1 neurons (Partridge and
Valenzuela, 2000).
This complex and diverse pharmacology has led to evaluation
of MFA in seizure control, pain syndromes, premenstrual
syndrome, asthma, Alzheimer’s disease and even alcohol induced
cognitive impairment in Zebrafish (Cimolai, 2013; Daniels et al.,
2016; Rajesh et al., 2018). A previous study from this lab
has indicated that systemic administration of MFA reduced
brain damage in rodents in vivo and was neuroprotective
against glutamate evoked excitotoxicity in rat hippocampal
neurons in vitro (Khansari and Halliwell, 2009). The aims of
the present study were therefore twofold: first, to determine
the intrinsic efficacy of MFA to protect against transient
cerebral ischemia by its direct infusion into the brain using
an in vivo model of stroke and, secondly, to investigate the
mechanism(s) underlying neuroprotection against glutamate-
induced excitotoxicity in vitro.
MATERIALS AND METHODS
Animal Model of Ischemic Stroke
All animal studies conformed to the guidelines outlined in
the Guide for the Care and Use of Laboratory Animals from
the National Institutes of Health and were approved by the
Galileo Pharmaceuticals (Santa Clara, CA, United States) Animal
Use Committee. 32 male Wistar rats weighing 300–350 g were
randomly assigned to one of four treatment groups (n = 8
per group). All animals were subjected to 2 h middle cerebral
artery occlusion (MCAO) using a modified intraluminal filament
technique (Figure 1). In brief, external, internal and common
carotid arteries were exposed through a midline incision on the
neck. A filament (Stren, Wilmington, DE, United States), its tip
rounded by heating, was inserted into the right common carotid
artery and advanced into the internal carotid artery to occlude
the origin of the middle cerebral artery. The filament was then
secured in place, the wound closed and the animals were allowed
to awaken. One hour after the induction of ischemia, animals
were assessed for functional impairment using the modified
Bederson grading system to verify accurate occlusion of the
middle cerebral artery: reduction of blood flow in this artery
is closely correlated with subsequent neurological impairment.
Only animals that demonstrated forelimb flexion, resistance to
lateral push and spontaneous contralateral circling were included
in the study. Animals that did not exhibit these behavioral
changes were excluded from the study because they may only
have a partial MCA occlusion. All neurological evaluations were
performed by an investigator blinded to the treatment regimen.
Two hours post-occlusion, the animals were re-anesthetized
to remove the filament and to allow reperfusion for 24 h.
Normothermia was maintained at 37.5 ± 1◦C for 6 h post-MCA
occlusion via external heating and cooling devices.
Intracerebroventricular Infusion
For targeted delivery to the brain, drugs were infused into the
left lateral ventricle using a 1 day (2001D) osmotic mini-pump
(Alza Corporation, Palo Alto, CA, United States). 24-h osmotic
pumps were filled for delivery according to the manufacturer’s
guidelines. Animals were anesthetized using 3.0% isoflurane, in
30% oxygen and then stabilized on a stereotaxic device (Harvard
Bioscience, Inc., Ann Arbor, MI, United States). A midline
sagittal incision about 3 cm long was made just behind the
eyes to expose the skull. Using bregma as the point of reference
(0 mm), the following coordinates were marked on the skull:
1.5 mm lateral and 2 mm posterior to the left of bregma (Jho
et al., 2003). Using a dental bur, a small hole was gently made in
the skull at the designated coordinates to expose the underlying
meninges. A brain infusion cannula (ALZET CO. Palo Alto, CA,
United States) connected to the pump was inserted 4 mm deep
from the surface of the brain. The length of the insertion was
adjusted using the spacers provided by the manufacturer. The
infusion cannula was then secured on the skull using dental
cement adhesive. To ensure the cannula was secured in place
and to prevent skin irritation caused by the dental cement, a
thin layer of bone wax was placed over the skull. Thereafter,
a pocket was made on the back of the animals’ neck using
small hemostats to accommodate the osmotic mini pump. The
pump was then connected to the brain-dwelling cannula via
a catheter for continuous infusion over 24 h and delivery at
8 µL/h.
Evaluation of Ischemic Damage
Twenty-four hours post-MCAO, animals were sacrificed by CO2
asphyxiation. The brain was removed quickly, and seven 2-mm-
thick coronal slices were cut from each brain using razor blades.
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FIGURE 1 | The experimental protocol and timeline for the middle cerebral artery occlusion (MCAO) experiments. Top left is a schematic dorsal view of rat brain and
middle cerebral artery and its major branches supplying blood to the temporoparietal cortex. The top right illustrates a ventral view of the intraluminal filament
occluding the left internal carotid artery beyond the bifurcation of the left middle cerebral artery to induce MCAO. The lower panel shows the timeline for drug
treatment, MCAO, reperfusion and post-MCAO evaluation.
The slices were immersed in a physiological solution containing
1.0% (w/v) 2,3,5-triphenyltetrazolium hydrochloride (Sigma
Chemical, Co., St. Louis, MO, United States) and incubated in
a 37◦C water bath for 15 min. A digital photograph of each
brain section was taken and used for data acquisition and analysis
using the MetaMorph Imaging System and analysis software
(Molecular Devices Corporation, San Jose, CA, United States).
The regions of analysis were the penumbra, infarct, edema
and the total ischemic brain damage (the sum of infarct
and penumbra) and compensated for ipsilateral swelling of
the brain as previously described (Khansari and Halliwell,
2009). The distinction between the core damage (infarct) and
the compromised region (penumbra) was assessed using an
automated color threshold function of the MetaMorph imaging
system, by which normal brain tissue appears red, infarct region
white, and penumbra as an intermediate pink surrounding
the infarct region (Figure 2, top). All the measurements were
obtained by an investigator blinded to the animal’s treatment
group.
Statistical Analysis
The minimum number of animals per group was calculated
using the SISA program (Quantitative Skills) for population size.
Sample size calculations assumed 95% power and a significance
level at p < 0.05. All group data are presented as means ± SEM.
A between-groups comparison of each region of interest was
carried out using an unpaired Student’s t-test (between two
groups) or a one-way ANOVA followed by post hoc Dunnett’s
multiple comparisons for groups larger than two (GraphPad
Prism, La Jolla, CA, United States).
Isolation and Culturing of Primary
Hippocampal Neurons
All animal studies conformed to the guidelines outlined in
the Guide for the Care and Use of Laboratory Animals
from the National Institutes of Health and were approved
by the University of Pacific Institutional Animal Care and
Use Committee. Hippocampal neurons were isolated from
19 days gestation embryos (Simonsen, Gilroy, CA, United States)
as described previously (Halliwell et al., 2002) and plated
on poly-D-lysine-coated 24-well plates in Neurobasal medium
supplemented with B27 (1%, v/v) (Invitrogen, Carlsbad, CA,
United States), Penicillin/Streptomycin (1%, v/v), and 0.5 mM
L-glutamine (Sigma-Aldrich). Cells were placed in an incubator
(Isotemp, Fisher Scientific, Inc., Santa Clara, CA, United States)
at 37◦C, 100% humidity and 5% CO2. Non-neuronal cell division
was halted by the addition of 10 µM cytosine arabinoside (Sigma-
Aldrich) after 2 days in culture. Fresh media was added every
3 days thereafter.
Glutamate-Evoked Neurotoxicity
Neurotoxicity was induced by exposure of the neuronal cell
cultures to mono-sodium glutamate (Na-glutamate). Briefly,
hippocampal neurons, 9 days in culture, were exposed to
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FIGURE 2 | Mefenamic acid (MFA) reduces brain damage following MCAO. Left inset shows a schematic of the rat brain with the diagonal lines representing the
seven 2 mm thick coronal brain sections obtained from each animal. The top right shows a coronal section 0.0 mm from bregma in a control MCAO animal. The
contralateral (non-injured) hemisphere appears red due to the reaction of viable cells with the TTC stain (red). The infarct, in the core of the ipsilateral (ischemic)
hemisphere in the temporal cortex, appears white due to the absence of live cells. The penumbra in the striatum appears pink due to a mixed population of both live
and dead cells. The lower panels show TTC stained serial sections (rostral to caudal is left to right) from a control (vehicle) and MFA (1 mg/kg) treated animal. Note
the large infarcted cortical areas in the vehicle treated animal.
10 min of 5 µM filter-sterilized Na-glutamate. Plates exposed to
glutamate were co-incubated with test compounds and placed
in a humidified incubator at 37◦C and 5% CO2. To terminate
glutamate exposure, cells were washed three times in modified
Neurobasal media (composition: 1% B27, 1% Pen/Strep, 0.5%
glutamine). Thereafter, compounds were added back to each well
so that the final concentration of the drug was the same during
the glutamate exposure and overnight incubation. Twenty-four
hours after exposure to Na-glutamate, cell death was quantified
by measuring the release of lactate dehydrogenase (LDH) in
the culture media using a CytoTox-96 non-radioactive assay kit
(Promega, Madison, WI, United States). Neuroprotection was
calculated as the percentage reduction in cell death induced by
exposure to Na-glutamate for 10 min.
RESULTS
Intrinsic Efficacy of Mefenamic Acid in
MCAO Model
The 32 animals were randomly assigned to one of four treatment
groups (with n = 8 per group) as follows: vehicle (NaOH,
0.1 M), MFA (0.5 mg/kg), MFA (1 mg/kg), and sodium salicylate
(1 mg/kg). The dose selection was based on our pilot study
(Supplementary Figure S1). Figure 1, illustrates a schematic
diagram of the experimetnal protocol. One hour prior to the
induction of cerebral ischemia (t = −1), a 24 h Alzet osmotic
mini pump (2001D) and brain infusion cannula was implanted
in the animal. As shown in Figure 2, ICV administration of
MFA (1 mg/kg) reduced the ischemic damage in all seven coronal
slices of the rat brain. Figure 3 summarizes that 0.5 mg/kg MFA
reduced total ischemic damage (TID) by 45% (p < 0.05), and
the infarct by 63% (p < 0.01), but had no significant effect on
the edema volume. Similarly, treatment with 1 mg/kg of MFA
decreased the TID by 47% (p < 0.05), and the infarct volume by
80% (p < 0.01). Notably edema volume was significantly reduced
from 103 ± 10 mm3 in vehicle treated group to 48 ± 11 mm3
in the MFA (1 mg/kg) group; this represents a 54% (p < 0.05)
reduction (Figure 3). Sodium Salicylate, a non-fenamate NSAID
tested as a reference compound also significantly reduced the
total ischemic brain damage by 42% (p < 0.05) and the infarct
volume by 59% (p < 0.01), but did not reduce the edema
volume. The reduction of infarct volume in MFA treated animals
shows a highly significant neuroprotective effect in the MCAO
model.
Neuroprotection by Fenamates in vitro
Hippocampal neurons maintained in cell culture for 9 days were
exposed to Na-glutamate (5 µM) for 10 min in the absence or
presence of either meclofenamic acid (10 or 100 µM), niflumic
acid (10 or 100 µM), flufenamic acid (10 or 100 µM) or MFA (10
or 100 µM). Doses were chosen based on the pharmacological
Frontiers in Neuroscience | www.frontiersin.org 4 February 2019 | Volume 13 | Article 64
fnins-13-00064 February 5, 2019 Time: 17:13 # 5
Khansari and Halliwell Neuroprotection by Mefenamic Acid
FIGURE 3 | Mefenamic acid and sodium salicylate are neuroprotective in the rodent transient MCAO model. The histograms show (A) penumbra volume, (B) infarct
volume, (C) total ischemic damage (TID) and (D) edema volume in animals treated with either MFA (0.5 or 1 mg/kg), sodium salicylate (1 mg/kg) or vehicle control.
Drugs were infused into the left lateral cerebral ventricle by osmotic mini pump for 24 h beginning 1 h prior to MCAO. MFA significantly reduced infarct, edema, and
TID; salicylate also reduced infarct and TID but the penumbra volume was not reduced in any of the treatment groups. Values are expressed as mean ± SEM for
n = 8 in each group. ∗p ≤ 0.05; ∗∗p ≤ 0.01.
properties of MFA (Coyne et al., 2007). As shown in Figure 4,
at 100 µM all selected fenamates significantly reduced cell
death in vitro. Treatment with MK-801 (10 µM) which we
used as a reference compound also showed almost complete
protection against glutamate-induced cell death. The rank order
of efficacy for protection against excitotoxicity by the fenamates
at 100 µM from highest was: mefenamic acid > flufenamic
acid ≥ meclofenamic acid > niflumic acid. These data therefore
show that neuroprotection is a property of the fenamates class of
NSAID.
Mechanism Underlying the
Neuroprotective Effects of Fenamates
Cyclooxygenase Inhibition
To address the hypothesis that the neuroprotective effects
of MFA and other fenamates results from COX inhibition,
indomethacin (10 or 100 µM), ibuprofen (10 or 100 µM),
and sodium salicylate (10 or 100 µM), were examined in our
glutamate-induced neurotoxicity assay. In keeping with initial
observations, cell death was reduced by 79% (p < 0.01) and 65%
(p < 0.01) by MFA (100 µM) and sodium salicylate (100 µM),
respectively (Figure 5). However, the NSAIDs, ibuprofen and
indomethacin did not reduce glutamate evoked cell death,
suggesting that COX inhibition alone is not sufficient to inhibit
excitotoxicity.
GABA Receptor Modulation
Positive allosteric modulators of the GABAA receptor are
neuroprotective in several experimental models of stroke (e.g.,
Fan et al., 2015) and a number of fenamates potentiate neuronal
GABAA receptors (Halliwell et al., 1999; Coyne et al., 2007).
Therefore, we tested the effects of MFA on glutamate-evoked
cell death in the presence of the GABAA channel blocker
picrotoxin, or the competitive GABAA receptor antagonist
bicuculline (Johnston, 2013) to evaluate the involvement of
GABAA receptors in neuroprotection (see Nelson et al., 2001).
In addition, the effects of two well-established potentiators
of GABAA receptors, i.e., the intravenous general anesthetic
sodium pentobarbital, and the sedative-hypnotic benzodiazepine
chlordiazepoxide, were also evaluated against glutamate-evoked
cell death.
Co-application of MFA (100 µM) with picrotoxin (100 µM)
did not significantly change the neuroprotective effects of MFA
(100 µM). In stark contrast, reduction in glutamate-induced cell
death by chlordiazepoxide (100 µM) or pentobarbital (100 µM)
was abolished by the co-application of picrotoxin (100 µM)
whereas picrotoxin itself had no effect on glutamate-induced
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FIGURE 4 | Excitotoxity was reduced by fenamate NSAIDs in vitro: (top) phase contrast photomicrographs of hippocampal neurons 9 days in culture untreated and
cells after exposure to glutamate (Glu, 5 µM), glutamate plus MFA (100 µM) or glutamate plus MK-801 (10 µM). (Bottom) Shows histogram summaries of similar
experiments conducted with mefenamic acid, flufenamic acid, niflumic acid or meclofenamic acid on glutamate induced cell death. Fenamates or MK-801 were
co-incubated during glutamate exposure and immediately after exposure for 24 h. Cell death was assayed 24 h post-exposure and significantly reduced
(∗∗p ≤ 0.01) by treatment with all the fenamates at 100 µM. Niflumic acid and meclofenamic acid, at 10 µM, also significantly reduced cell death by 54% (∗p ≤ 0.05)
and 56% (∗∗p ≤ 0.01) respectively. Note that MK-801 even reduced LDH (cell death) below the untreated cells. The scale bar is 40 microns at 300x magnification.
cell death (Figure 6, top). Consistent with these findings,
bicuculline (10 µM) did not change the level of cell death
induced by glutamate and co-incubation of bicuculline (10 µM)
with MFA did not significantly change the neuroprotective
effect of MFA alone (Figure 6, bottom). In contrast, bicuculline
(10 µM) significantly reduced the neuroprotective effects of
both chlordiazepoxide (100 µM) and pentobarbital (100 µM)
against glutamate excitoxicity. Collectively, these data show that
the ability of MFA to reduce glutamate-evoked cell death is not
dependent on GABAA receptor modulation.
Potassium Channel Activation
Nicorandil, a non-selective KATP channel opener is
neuroprotective against glutamate-induced cell death (Nagy
et al., 2004). Notably, MFA is also reported to activate KATP
channels (Teramoto et al., 2003). Therefore, we addressed
whether potassium channel activation might be an underlying
mechanism for the neuroprotection observed with MFA.
To inhibit potassium channels, tetraethylammonium (TEA)
(Heurteaux et al., 1993), a broad spectrum potassium channel
blocker, which inhibits nicorandil induced outward currents
(Kajioka et al., 1990) was tested on the actions of MFA and on
the effects of nicorandil in our excitotoxicity assay.
Consistent with our previous experiment and as shown in
Figure 7, cell death was reduced when cultures were incubated
with MFA (100 µM) or nicorandil (100 µM) by 65% (p ≤ 0.01)
and 60% (p ≤ 0.01), respectively. Treatment with TEA (30 mM)
FIGURE 5 | Impact of Cyclooxygenase inhibition on glutamate-evoked
neurotoxicity: hippocampal neurons 9 days in culture were exposed to
glutamate (5 µM) in the absence (control) or presence of either sodium
salicylate (SAL), indomethacin (INDO), or ibuprofen (IBU) (each at 10 and
100 µM). Drugs were co-incubated during glutamate exposure and
immediately after exposure for 24 h. Cell death was measured 24 h
post-exposure using Cytotox-96. Sodium salicylate significantly reduced cell
death by 56% (∗∗p ≤ 0.01) and 65% (∗∗p ≤ 0.01) at 10 and 100 µM,
respectively. However, neither indomethacin nor ibuprofen reduced
glutamate-induced cell death. The NMDA channel blocker, MK-801 (10 µM)
reduced cell death by 98% (∗∗p ≤ 0.01).
alone however did not significantly reduce cell death when
compared with cultures exposed to glutamate. Post hoc analysis
showed that co-application of MFA (100 µM) and TEA (30 mM)
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FIGURE 6 | Impact of GABAA receptor and ion channel inhibition on the neuroprotective effects of MFA in vitro: hippocampal neurons cultured for 9 days were
exposed to glutamate (5 µM) and test drugs by co-incubating during exposure and immediately after exposure for 24 h. Cell death was quantified using Cytotox-96
at 24 h post-exposure. (Top) Treatment with MFA (100 µM), chlordiazepoxide (CDZ, 100 µM), or sodium pentobarbital (Pento, 100 µM) reduced glutamate induced
cell death by 62, 74, and 81% (∗∗p ≤ 0.01) respectively. Picrotoxin (PTX, 100 µM) abolished the neuroprotective effect of CDZ and sodium pentobarbital on
glutamate-evoked cell death but did not significantly alter the action of MFA. Picrotoxin (100 µM) alone did not reduce glutamate evoked cell death. (Bottom) MFA,
CDZ or pentobarbital (all tested at 100 µM) reduced glutamate induced cell death by 62, 74, and 81% (∗∗p ≤ 0.01) respectively. Bicuculline (BIC, 10 µM) abolished
the effect of pentobarbital and significantly reduced the neuroprotective effect of CDZ on glutamate induced cell death, but failed to alter the effect of MFA.
Bicuculline (10 µM) alone did not reduce glutamate evoked cell death ∗p < 0.05.
had little or no effect on the neuroprotective property of MFA. In
contrast, the effect of nicorandil (100 µM) on glutamate-evoked
cell death was abolished by TEA (30 mM).
DISCUSSION
The present study was undertaken to investigate the hypothesis
that fenamate NSAIDs have intrinsic neuroprotective properties
against ischemic stroke in vivo and to establish the underlying
pharmacological mechanisms in vitro. Our hypothesis was based
on observations that (i) fenamates have a unique spectrum
of pharmacological actions that may be important in the
pathogenesis of stroke and (ii) a previous report that MFA
administered intravenously reduces ischemic brain damage
induced by transient ischemic stroke in the rodent MCAO model
of stroke (Khansari and Halliwell, 2009).
To evaluate the hypothesis that MFA efficacy is due to
a direct CNS effect, rather than a peripheral and indirect
site of action, we used an intracerebroventricular (ICV)
route of drug delivery to the CNS. A continuous infusion
for 24 h at a constant rate also enhances the availability
of the drug during the course of injury when its action is
likely most needed and the intraluminal filament model
of stroke is a well-established and validated animal model
to study neuroprotection (Herson and Traystman, 2014).
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FIGURE 7 | Involvement of K channels in the neuroprotective effects of MFA
in vitro: hippocampal neurons in culture for 9 days were exposed to glutamate
(5 µM). Drugs were co-incubated during glutamate exposure and immediately
after for 24 h. Cell death was quantified using the Cytotox-96 24 h later.
Treatment with MFA (100 µM) or nicorandil (NIC, 100 µM) reduced glutamate
mediated cell death by 65 and 60% (∗∗p ≤ 0.01) respectively.
Tetraethylammonium (TEA, 30 mM) alone did not significantly alter the level of
glutamate induced cell death. Co-application of TEA (30 mM) completely
abolished the neuroprotective effect of nicorandil (100 µM) but co-incubation
of TEA (30 mM) with MFA (100 µM) did not significantly affect the
neuroprotective actions of this fenamate NSAID.
MFA administration significantly reduced the total ischemic
brain damage and the infarct volume to an extent normally
only achieved with a potent neuroprotectant like MK-801
(Dizilopine R©). Notably, edema volume was also reduced
significantly in MFA treated animals (but not in the sodium
salicylate treated group). These data are the first demonstration
of neuroprotection in vivo against MCAO with direct infusion of
the NSAID, MFA.
In vitro, four fenamate NSAIDs were tested against glutamate
induced excitotoxicity. Treatment with MFA, flufenamic acid,
niflumic acid or meclofenamic acid all significantly reduced cell
death. Consistent with our observations, Chen and colleagues,
have shown that exposure of the chick retina in vitro to
oxygen-glucose deprivation can be attenuated by mefenamic
acid, flufenamic acid, and meclofenamic acid (Chen et al.,
1998). In addition, these authors also reported a neuroprotective
effect of fenamates against the direct application of NMDA or
Kainate to the retinal slices. Together, these findings show that
fenamate NSAIDs have significant neuroprotective properties
against excitotoxicity induced cell death.
The neuroprotective effects of MFA and other fenamates may
result from a single or a combination of several mechanisms.
To address the importance of each of the potential mechanisms
against glutamate neurotoxicity, a prototype agent which shares
a specific component of the fenamates activity was evaluated in
hippocampal neuron cell cultures. Inhibition of cyclooxygenases
by fenamates is well-documented. We therefore compared the
neuroprotective effects of MFA with two potent non-selective
COX inhibitors, indomethacin and ibuprofen and found they
had no effect on glutamate-induced cell death. In contrast,
salicylate reduced cell death. Consistent with our findings,
De Cristóbal et al. (2002), reported that indomethacin did
not protect rat cortical neurons in culture against oxygen-
glucose deprivation whereas aspirin and sodium salicylate were
neuroprotective (De Cristóbal et al., 2002). Taken together, the
lack of neuroprotection by indomethacin and ibuprofen, and the
wide spectrum of pharmacological properties of both MFA and
sodium salicylate suggest that attenuation of glutamate induced
cell death may result from actions other than COX I and II
inhibition.
Modulation of GABAA receptors has been associated with
neuroprotection in several experimental models of cerebral
ischemia (e.g., Håberg et al., 2001) and fenamates have been
shown to modulate GABAA receptors in electrophysiological
studies of primary neurons and cells expressing recombinant
human GABAA receptors (Halliwell et al., 1999; Coyne et al.,
2007). Here we show that pentobarbital and chlordiazepoxide
greatly reduced neuronal cell death. Rekling (2003) previously
reported that phenobarbital and chlordiazepoxide inhibited
oxygen-glucose deprivation induced cell death in rat
hippocampal slices. These data are consistent with the hypothesis
that potentiation of GABAA receptors could be an important
underlying mechanism against excitotoxicity (Foster and Kemp,
2006; Amantea and Bagetta, 2017). However, co-incubation of
MFA with either picrotoxin, a non-competitive GABA gated
chloride channel blocker (Squires et al., 1983) or the competitive
GABAA receptor antagonist, bicuculline (Johnston, 2013), had
no effect on the efficacy of MFA to inhibit glutamate-induced
cell death. In stark contrast, reductions in glutamate cell death
by pentobarbital and chlordiazepoxide were completely reversed
by both GABAA antagonists. Our observations, together with
the finding that niflumic acid, which inhibits GABAA receptors
(Sinkkonen et al., 2003), indicate that fenamate neuroprotection
does not depend on modulation of GABA-gated chloride
channels.
Some evidence suggests that the opening of potassium
channels leads to efflux of potassium ions and counteracts the
depolarizing effect of ischemic insult (Heurteaux et al., 1993;
Veltkamp et al., 1998). Several types of potassium channels have
been identified in the brain, including ATP-sensitive potassium
channels present in the cerebrovasculature and the hippocampus
(Rosenblum, 2003). Teramoto et al. (2003) reported that a
unique property of MFA is activation of both ATP-sensitive
potassium channels and intracellular calcium activated potassium
channels. We therefore addressed the effects of the potassium
channel opener, nicorandil (SG-209), a KATP channel opener
(Levin et al., 2001) on glutamate-evoked cell death and found
it profoundly reduced glutamate induced cell death. Thus, to
investigate the role of potassium channel activation by MFA in
reducing glutamate-induced cell death, TEA, a broad spectrum
potassium selective ion channel blocker was co-incubated with
MFA or nicorandil. Our results showed that TEA completely
abolished the effect of nicorandil against glutamate evoked cell
death but had little or no effect on the neuroprotective actions of
MFA. These data therefore support the hypothesis that a variety
of potassium channels activators might be useful neuroprotective
agents (Heurteaux et al., 1993; Hewawasam et al., 2003), but
this property of MFA is not likely to be the mechanism for its
neuroprotective actions.
Mefenamic acid has been shown to reduce cell death induced
by amyloid β1−42 in neurally differentiated PC-12 cells in vitro
and to attenuate the cognitive impairments of amyloid β1−42
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in a rodent model of spatial learning and memory in the water
maze task (Joo et al., 2006). These neuroprotective effects were
suggested to result from the efficacy of MFA to inhibit the release
of reactive oxygen species (ROS), nitric oxide accumulation
and mitochondrial cytochrome c, and upregulation of the anti-
apoptotic protein, Bcl-XL. Preliminary experiments in this lab
also show that MFA reduces ROS released from neurons exposed
to the excitotoxin glutamate (Supplementary Figure S2) but
further studies are underway. In a recent study, MFA was
additionally reported to inhibit the NLRP3 inflammasome (a
multi-protein complex implicated in inflammatory diseases)
via inhibition of the volume-regulated anion channel and to
protect Lister hooded rats against Aβ1−42 induced impairments
in the novel object recognition task (Daniels et al., 2016).
The data from these two studies therefore indicates additional
mechanisms for neuroprotection observed with fenamates
against inflammation in the brain and have also suggested that
fenamates might be usefully repurposed to target inflammatory
disorders such as Alzheimer’s disease (Mangan et al., 2018).
Further studies, however, are therefore required to delineate
the precise mechanisms of action of fenamates against ischemic
insult and neurodegeneration.
CONCLUSION
Our own experiments show that MFA has significant efficacy
to reduce brain damage from ischemic stroke in vivo and that
fenamates, as a class, an ability to reduce neuronal cell death
from excitotoxicity in vitro. MFA has a unique pharmacology,
including an ability to inhibit cyclooxygenases, modulate
GABAA receptors, activate potassium channels and inhibit the
inflammasome, all of which may contribute synergistically to its
neuroprotective efficacy. On the basis of the pharmacological
properties of fenamates, it may be of considerable value to
further address their neuroprotective properties experimentally
and clinically, as adjunctive therapy in the treatment of ischemic
stroke.
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FIGURE S1 | Pilot data showing that 1 mg/kg mefenamic acid, administered ICV
reduces brain damage following MCAO. (A) Shows a 2 mm thick coronal brain
section −1 mm from bregma in an animal given 1 mg/kg mefenamic acid (MFA) by
ICV (see section “Materials and Methods” for further details). The contralateral
(non-injured) hemisphere is red due to the reaction of viable cells with the TTC
stain (red). The infarct, in the core of the ipsilateral (ischemic) hemisphere is white
due to the absence of live cells. (B) Show a 2 mm thick coronal brain section
(−1 mm from bregma) from an animal given 0.1 mg/kg MFA ICV. Note the large
infarcted cortical areas in this brain section.
FIGURE S2 | Impact of NSAIDs on reactive oxygen species (ROS) formation: ROS
was assayed using 2′, 7′-dichlorofluorescein diacetate (DCFH-DA). This dye
rapidly enters the cells and is desterified to the ionic dichlorofluorescein (DCFH).
DCFH is oxidized to the fluorescent 2′, 7′-dichlorofluorescein (DCF) by ROS.
A microplate fluorescent reader was used to measure the fluorescence at
excitation and emission of 485 and 530 nm, respectively. Primary hippocampal
neurons were washed twice after treatment and incubated for 15 min at 37◦C with
10 µM dye in media without serum and phenol red. ROS formation was
significantly increased in hippocampal cultures after exposure to glutamate (5 µM;
p < 0.01). In contrast, ROS levels in culture media decreased significantly when
treated with MFA (30 or 100 µM). ROS was also reduced in cultures treated with
MK-801 (10 µM) and indomethacin (100 µM). The experiment was conducted
using a single culture of hippocampal neurons with each condition ran in triplicate.
∗p ≤ 0.05; ∗∗p ≤ 0.01).
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